Nutritional Supplement

Fish Oil & Cod Liver Oil (EPA & DHA)

  • Heart and Circulatory Health

    High Triglycerides

    Many double-blind trials have shown that fish oil containing EPA and DHA lowers triglycerides levels.
    High Triglycerides
    ×
     

    Many double-blind trials have demonstrated that fish oils (also called fish-oil concentrates) containing EPA and DHA (mentioned above) lower TG levels.1 The amount of fish oil used in much of the research was an amount that provided 3,000 mg per day of omega-3 fatty acids. To calculate how much omega-3 fatty acid is contained in a fish oil supplement, add together the amounts of EPA and DHA. For example, a typical 1,000-mg capsule of fish oil provides 180 mg of EPA and 120 mg of DHA (total omega-3 fatty acids equals 300 mg). Ten of these capsules would contain 3,000 mg of omega-3 fatty acids. Other sources of omega-3 fatty acids, such as flaxseed oil, do not lower TGs. While flaxseed oil has other benefits, it should not be used for the purpose of reducing TGs.

    Cod liver oil, another source of omega-3 fatty acids, has also been found to lower TGs.2 Cod liver oil is less expensive than the fish oil concentrates discussed previously. However, cod liver oil also contains relatively large amounts of vitamin A and vitamin D; too much of either can cause side effects. In contrast, fish oil concentrates have little or none of these vitamins. Individuals wishing to use cod liver oil as a substitute for a fish-oil concentrate should consult a doctor.

    Omega-3 fatty acids from fish oil and cod liver oil have been reported to affect blood in many other ways that might lower the risk of heart disease.3 However, these supplements sometimes increase LDL cholesterol—the bad form of cholesterol. A doctor can check to see if fish oil has this effect on an individual. Research shows that when 900 mg of garlic extract is added to fish oil, the combination still dramatically lowers TG levels but no longer increases LDL cholesterol.4 Therefore, it appears that taking garlic supplements may be a way to avoid the increase in LDL cholesterol sometimes associated with taking fish oil. People who take fish oil may also need to take vitamin E to prevent the oil from undergoing potentially damaging oxidation in the body.5 It is not known how much vitamin E is needed to prevent such oxidation. The amount required would presumably depend on the amount of fish oil used. In one clinical trial, 300 IU of vitamin E per day prevented oxidation damage in individuals taking 6 grams of fish oil per day.6

    Hypertension

    EPA and DHA, the omega-3 fatty acids found in fish oil, have been shown to lower blood pressure.
    Hypertension
    ×
    EPA and DHA, the long-chain polyunsaturated omega-3 fatty acids found in fish oil, have been shown to improve blood vessel function and lower blood pressure.7 Although a large observational study that followed 12,279 men for an average of 15.8 years found no relationship between omega-3 fatty acid intake and risk of high blood pressure,8 multiple studies have noted higher blood levels of these fatty acids, and especially DHA, are associated with reduced incidence of hypertension.9 Furthermore, a meta-analysis of 70 randomized controlled trials found supplementing with at least 2 grams of EPA plus DHA per day significantly reduces systolic and diastolic blood pressure, and the effect is stronger in those with hypertension.10

    Congestive Heart Failure

    In a double-blind study of people with chronic heart failure, a combination of EPA and DHA for four years resulted in a small but statistically significant protection against death or hospitalization for cardiovascular reasons.
    Congestive Heart Failure
    ×

    In a double-blind study of patients with chronic heart failure, supplementation with the fatty acids present in fish oil for an average of four years resulted in a small but statistically significant decrease in the number of patients who died or were hospitalized for cardiovascular reasons. The treatment consisted of 850 to 882 mg per day of a mixture of eicosapentaenoic acid and docosahexaenoic acid (as their ethyl esters).11 In another double-blind trial, supplementation with eicosapentaenoic acid and docosahexaenoic acid improved heart function and decreased the number of hospitalizations in patients with heart failure due to dilated cardiomyopathy.12

    Atherosclerosis

    Fish oil may reduce risk factors for atherosclerosis and heart disease. One trial showed that people who took fish oil had a slowing of the progression of their arterial plaque and had a decrease in cardiovascular events such as heart attack and stroke.
    Atherosclerosis
    ×
     

    Supplementation with fish oil, rich in omega-3 fatty acids, has been associated with favorable changes in various risk factors for atherosclerosis and heart disease in some,13,14,15,16,17,18 but not all, studies.19,20,21 A double-blind trial showed that people with atherosclerosis who took fish oil (6 grams per day for 3 months and then 3 grams a day for 21 months) had significant slowing of progression of atherosclerotic plaques and a decrease in cardiovascular events (for example, heart attack and stroke) compared with those who did not take fish oil.22 These results contradict the findings of an earlier controlled trial in which fish oil supplementation for two years (6 grams per day) did not promote major favorable changes in the diameter of atherosclerotic coronary arteries.21

    Angina

    Fish oil has been shown to reduce chest pain and the need for nitroglycerin. Taking vitamin E with fish oil may protect the oil from undergoing potentially damaging oxidation in the body.
    Angina
    ×
     

    Fish oil, which contains the fatty acids known as EPA and DHA, has been studied in the treatment of angina. In some studies, enough fish oil to provide a total of about 3 grams of EPA and 2 grams of DHA has reduced chest pain as well as the need for nitroglycerin;23 other investigators could not confirm these findings.24 People who take fish oil may also need to take vitamin E to protect the oil from undergoing potentially damaging oxidation in the body.25 It is not known how much vitamin E is needed to prevent such oxidation; the amount required would presumably depend on the amount of fish oil used. In one study, 300 IU of vitamin E per day prevented oxidation damage in individuals taking 6 grams of fish oil per day.26

    Heart Attack

    Supplementing with fish oil may reduce the chances of having another heart attack.
    Heart Attack
    ×
    Fish oil contains the beneficial omega-3 fatty acids EPA and DHA, which have led to partial reversal of atherosclerosis in a double-blind trial.27 In another double-blind trial, individuals were given either fish oil (containing about 1 gram of EPA and 2/3 gram of DHA) or mustard oil (containing about 3 grams alpha linolenic acid, another omega-3 fatty acid) 18 hours after a heart attack. Both groups experienced fewer nonfatal heart attacks compared to a placebo group, while the fish oil group also experienced fewer fatal heart attacks.28 The largest published study on omega-3 fatty acids for heart attack prevention was the preliminary GISSI Prevenzione Trial,29 which reported that 850 mg of omega-3 fatty acids from fish oil per day for 3.5 years resulted in a 20% reduction in total mortality and a 45% decrease in sudden death. Other investigators suggest that fish oil reduces the amount of heart muscle damage from a heart attack and enhances the effect of blood-thinning medication.30 People wishing to supplement with fish oil should take fish oil supplements that include at least small amounts of vitamin E, which may protect this fragile oil against free radical damage.31

    Intermittent Claudication

    In one study, men with intermittent claudication who drank a milk product fortified with fish oil, vitamin B6, folic acid, vitamin E, oleic acid, and alpha-linolenic acid could walk further without pain than those who drank regular milk.
    Intermittent Claudication
    ×
     

    Men with intermittent claudication consumed a fortified milk product or regular milk daily for one year. The fortified product provided daily 130 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid (EPA and DHA, two fatty acids in fish oil), small amounts of supplemental vitamin E, folic acid, and vitamin B6, and additional amounts of oleic acid and alpha-linolenic acid. Compared with regular milk, the fortified milk product significantly increased the distance the participants could walk before the onset of pain.32

    Raynaud’s Disease

    Supplementing with fish oil may reduce the severity of blood-vessel spasm.
    Raynaud’s Disease
    ×

    In a double-blind trial, supplementation with 12 large capsules of fish oil per day (providing 4 grams of eicosapentaenoic acid [EPA] per day) for 6 or 12 weeks reduced the severity of blood-vessel spasm in 5 of 11 people with Raynaud’s phenomenon.33 Fish oil was effective in people with primary Raynaud’s disease, but not in those whose symptoms were secondary to another disorder.

    Cardiac Arrhythmia

    Fish oil has been shown to reduce the frequency of abnormal heartbeats in some trials.
    Cardiac Arrhythmia
    ×
     

    In a double-blind trial, people with a type of arrhythmia known as ventricular premature complexes were supplemented for 16 weeks with either 15 ml (1 tbsp) per day of fish oil or a similar amount of safflower oil as placebo. Patients taking the fish oil had a significantly reduced frequency of abnormal heartbeats compared with those receiving placebo, and 44% of those receiving fish oil experienced at least a 70% reduction in the frequency of abnormal beats.34 In a separate study, however, men given 20 ml (4 tsp) of cod liver oil per day for six weeks, beginning one week after a heart attack, had the same frequency of irregular heart beats as did men given no supplemental oil.35 In a double-blind study, people who had a history of certain potentially life-threatening arrhythmias—sustained ventricular tachycardia or ventricular fibrillation—had an increase in the recurrence rate of these arrhythmias when they took fish oil.36 A similar study found no adverse effect of fish oil supplements in people with these serious arrhythmias.37 Because of these conflicting findings, people with a history of either of these arrhythmias should consult a doctor before taking fish oil.

    Chronic Obstructive Pulmonary Disease

    The omega-3 fatty acids found in fish oil have been linked to reduced risk of COPD.
    Chronic Obstructive Pulmonary Disease
    ×
     

    A greater intake of the omega-3 fatty acids found in fish oils has been linked to reduced risk of COPD,38 though research has yet to investigate whether fish oil supplements would help people with COPD. In a double-blind trial, people with COPD received a fatty acid supplement (providing daily 760 mg of gamma-linolenic acid, 1,200 mg of alpha-linolenic acid, 700 mg of eicosapentaenoic acid, and 340 mg of docosahexaenoic acid) or a placebo (80% palm oil and 20% sunflower oil) during an eight-week rehabilitation program. Compared with the placebo, the fatty acid supplement significantly improved exercise capacity.39 While two of the fatty acids supplied in this supplement (eicosapentaenoic acid [EPA] and docosahexaenoic [DHA] acid) are found in fish oil, is not known which components of the supplement were most responsible for the improvement. Gamma-linolenic acid is found in evening primrose oil, black currant seed oil, and borage oil; alpha-linolenic acid is found in flaxseed oil and other oils.

  • Stress and Mood Management

    Depression

    Depressed people have been reported to have low amounts of omega-3 fatty acids. Taking fish oil can replenish stores and stave off depression.
    Depression
    ×
     

    Omega-3 fatty acids found in fish oil, particularly DHA, are needed for normal nervous system function. Depressed people have been reported to have lower omega-3 fatty acid levels (for example, DHA) than people who are not depressed.40,41,42,43 Low levels of the other omega-3 fatty acid from fish, EPA, have correlated with increased severity of depression.44 In some double-blind trials, supplementation with various amounts of fish oil was beneficial for the treatment of depression in both children and adults,45,46 but fish oil was ineffective in other double blind trials.47,48

    EPA alone has also been reported to be beneficial. There is one case report of a man with a long history of severe depression who showed clear improvement within one month of starting a purified EPA supplement (4 grams per day of the ethyl ester of eicosapentaenoic acid [E-EPA]).49 In a double-blind study, supplementation with E-EPA for 12 weeks was significantly more effective than a placebo at relieving symptoms of depression.50 E-EPA was beneficial, even though the participants in the study had failed to respond adequately to conventional antidepressant drugs. The conventional medications were continued during treatment with E-EPA or placebo. An effective level of intake was 1 gram per day, whereas larger amounts of E-EPA resulted in little or no benefit. The authors of the study suggested that taking too much E-EPA might cause an imbalance with other essential fatty acids, which could reduce the effectiveness of the treatment.

    Anxiety

    In a double-blind trial, fish oil was significantly more effective than a placebo in improving anxiety levels for substance abusers.
    Anxiety
    ×
    In a double-blind trial, fish oil was significantly more effective than a placebo in improving anxiety levels in a group of substance abusers (alcohol, cocaine, and/or heroin).51 The fish oil used in this study provided 3 grams per day of omega-3 fatty acids and was given for three months.
  • Women's Health

    Dysmenorrhea

    A fish oil supplement containing EPA and DHA may help prevent menstrual syndromes.
    Dysmenorrhea
    ×
    Diets low in omega-3 fatty acids (EPA and DHA) have been associated with menstrual pain.52 In one double-blind trial, supplementation with fish oil, a good source of omega-3 fatty acids, led to a statistically significant 37% drop in menstrual symptoms. In that report, adolescent girls with dysmenorrhea took an unspecified amount of fish oil that provided 1,080 mg of EPA and 720 mg of DHA per day for two months to achieve this result.53 A double-blind trial found that the same amount of EPA and DHA plus 7.5 mcg per day of vitamin B12 led to a greater than 50% decrease in menstrual symptoms, but a group taking only fish oil did not obtain as much relief.54 Six grams of fish oil per day provides the approximate levels of EPA and DHA used in these trials. In another double-blind trial, 1 gram per day of fish oil significantly decreased pain intensity, compared with a placebo, in women with dysmennorhea.55

    Pregnancy and Postpartum Support

    Supplementing with fish oil (providing the omega-3 fatty acids EPA and DHA) significantly reduced recurrence of premature delivery, according to one analysis.
    Pregnancy and Postpartum Support
    ×
     

    Supplementation with fish oil (providing either 2.7 g or 6.1 g per day of the omega-3 fatty acids EPA and DHA) significantly reduced recurrence of premature delivery, according to data culled from six clinical trials involving women with a high risk for such complications.56 Fish oil supplementation did not prevent premature delivery of twin pregnancies, nor did it have any preventive effect against intrauterine growth retardation or pregnancy-induced hypertension. Fish oils should be free of contaminants, such as mercury and organochlorine pesticides. Women who eat substantial amounts of certain types of seafood (e.g., swordfish, tuna) may be consuming contaminants that can increase the risk of brain and nervous system abnormalities in their offspring. Exposure to mercury and polychlorinated biphenyls (PCBs) was found to be increased in relation to maternal intake of seafood. Higher exposure to these toxic contaminants has been linked to an increased risk of deficits in the developing brains and nervous systems of the children.57

    Pregnancy and Prenatal Growth

    The DHA found in fish oil is essential for the development of the visual system in infants.
    Pregnancy and Prenatal Growth
    ×
    The DHA found in fish oil is essential for the development of the visual system in infants.58 In one double-blind study, 103 term infants were randomly assigned to receive either formula with no docosahexaenoic acid (DHA) or arachidonic acid (ARA) or formula supplemented with DHA and ARA at concentrations similar to those found in human milk, starting when they were six days old. Visual maturation was assessed by measuring sweep visual evoked potential at ages 6, 17, 26, and 52 weeks. At each age, the supplemented group measured better, which led researchers to conclude that long-term supplementation of infant formula with DHA and ARA in amounts typical in human milk may help enhance visual development during the first year of life.

    Endometriosis

    Fish oil may reduce the severity of endometriosis, and it has been shown to improve symptoms of dysmenorrhea (painful menstruation), which may be caused by endometriosis.
    Endometriosis
    ×
     

    Animal research suggests that fish oils may reduce the severity of endometriosis,59,60 and fish oils have been shown to improve symptoms of dysmenorrhea (painful menstruation),61 which may be caused by endometriosis. Therefore, while no specific research has been done on the effects of fish oils in women with endometriosis, some health practitioners recommend several grams of fish oil per day for this condition.

  • Healthy Aging/Senior Health

    Macular Degeneration

    In one study, supplementing with a proprietary blend of acetyl-L-carnitine, fish oil, and coenzyme Q10 improved visual function in people with macular degeneration.
    Macular Degeneration
    ×
     

    In a double-blind study, supplementation with a proprietary blend of acetyl-L-carnitine, omega-3 fatty acids from fish oil, and coenzyme Q10 for 12 months resulted in an improvement in both visual function and in objective findings on eye examination (a decrease in the drusen-covered area on the retina).62

    Macular Degeneration

    A diet high in omega-3 fatty acids, especially from fish, has been associated with lower risks of age-related macular degeneration.
    Macular Degeneration
    ×
    An assessment of 3,654 Australians aged 49 years or older found an association between a diet high in omega-3 fatty acids from fish and a lower risk of age-related macular degeneration.63

    Alzheimer’s Disease

    Fish oil may help slow the rate of cognitive decline in people with very mild impairment.
    Alzheimer’s Disease
    ×
     

    In a double-blind trial, supplementing with the fatty acids present in fish oil (0.6 grams per day of EPA and 1.7 grams per day of DHA) for six months was not beneficial in people with Alzheimer's disease. However, in the subgroup of people with very mild cognitive impairment, supplementation with these fatty acids slowed the rate of cognitive decline compared with a placebo.64

  • Joint Health

    Rheumatoid Arthritis

    Fish oil has anti-inflammatory effect and may help reduce pain. Many trials have proven that omega-3 fatty acids in fish oil partially relieve symptoms of rheumatoid arthritis.
    Rheumatoid Arthritis
    ×

    Many double-blind trials have proven that omega-3 fatty acids in fish oil, called EPA and DHA, partially relieve symptoms of RA.65,66,67,68,69,70,71,72,73 The effect results from the anti-inflammatory activity of fish oil.74 Many doctors recommend 3 grams per day of EPA and DHA, an amount commonly found in 10 grams of fish oil. Positive results can take three months to become evident. In contrast, a double-blind trial found flaxseed oil (source of another form of omega-3 fatty acid) not to be effective for RA patients.75

    Osteoarthritis

    The omega-3 fatty acids present in fish oil, EPA and DHA, have anti-inflammatory effects and may relieve pain.
    Osteoarthritis
    ×

    The omega-3 fatty acids present in fish oil, EPA and DHA, have anti-inflammatory effects and have been studied primarily for rheumatoid arthritis, which involves significant inflammation. However, osteoarthritis also includes some inflammation.76 In a 24-week controlled but preliminary trial studying people with osteoarthritis, people taking EPA had “strikingly lower” pain scores than people who took placebo.77 However, in a double-blind trial by the same research group, supplementation with 10 ml of cod liver oil per day was no more effective than a placebo.78

  • Skin Protection

    Psoriasis

    Fish oil has been found to reduce the severity of psoriasis and improve skin lesions. It also may help prevent increased triglyceride levels that result from certain psoriasis drugs.
    Psoriasis
    ×
     

    In a double-blind trial, fish oil (10 grams per day) was found to improve the skin lesions of psoriasis.79 In another trial, supplementing with 3.6 grams per day of purified eicosapentaenoic acid (EPA, one of the fatty acids found in fish oil) reduced the severity of psoriasis after two to three months.80,81 That amount of EPA is usually contained in 20 grams of fish oil, a level that generally requires 20 pills to achieve. However, when purified EPA was used in combination with purified docosahexaenoic acid (DHA, another fatty acid contained in fish oil), no improvement was observed.82

    Additional research is needed to determine whether fish oil itself or some of its components are more effective for people with psoriasis. One trial showed that applying a preparation containing 10% fish oil directly to psoriatic lesions twice daily resulted in improvement after seven weeks.83 In addition, promising results were reported from a double-blind trial in which people with chronic plaque-type psoriasis received 4.2 g of EPA and 4.2 g of DHA or placebo intravenously each day for two weeks. Thirty-seven percent of those receiving the essential fatty acid infusions experienced greater than 50% reduction in the severity of their symptoms.84

    Supplementing with fish oil also may help prevent the increase in blood levels of triglycerides that occurs as a side effect of certain drugs used to treat psoriasis (e.g., etretinate and acitretin).85

    Eczema

    Supplementing with fish oil can supply anti-inflammatory fatty acids that are missing in many people with eczema.
    Eczema
    ×
     

    Ten grams of fish oil providing 1.8 grams of EPA (eicosapentaenoic acid) per day were given to a group of eczema sufferers in a double-blind trial. After 12 weeks, those using the fish oil experienced significant improvement.86,87 According to the researchers, fish oil may be effective because it reduces levels of leukotriene B4, a substance that has been linked to eczema.88 The eczema-relieving effects of fish oil may require taking ten pills per day for at least 12 weeks. Smaller amounts of fish oil have been shown to lack efficacy.89

    One trial using vegetable oil as the placebo reported that fish oil was barely more effective than the placebo (30% vs. 24% improvement).90 As vegetable oil had previously been reported to have potential therapeutic activity, the apparent negative outcome of this trial should not dissuade people with eczema from considering fish oil.

    Photosensitivity

    In one trial, supplementing with fish oil reduced photosensitivity in 90% of people suffering from polymorphous light eruptions.
    Photosensitivity
    ×
     

    In a small preliminary trial, supplementation with fish oil (10 grams per day for three months) reduced photosensitivity in 90% of people suffering from polymorphous light eruptions.91

  • Oral Health

    Tooth Decay

    One trial showed that children given cod liver oil for an entire school year had over 50% fewer new cavities.
    Tooth Decay
    ×
     

    One older controlled trial found that children given 3 teaspoons of cod liver oil per day (containing roughly 800 IU of vitamin D) for an entire school year had over 50% fewer new cavities.92 These promising results have not been followed up with modern placebo-controlled trials.

  • Brain Health

    Anxiety

    In a double-blind trial, fish oil was significantly more effective than a placebo in improving anxiety levels for substance abusers.
    Anxiety
    ×
    In a double-blind trial, fish oil was significantly more effective than a placebo in improving anxiety levels in a group of substance abusers (alcohol, cocaine, and/or heroin).93 The fish oil used in this study provided 3 grams per day of omega-3 fatty acids and was given for three months.

    Schizophrenia

    Omega-6 and omega-3 fatty acids appear to be deficient or improperly used in people with schizophrenia. Supplementing with fish oil may correct an imbalance and improve symptoms.
    Schizophrenia
    ×
     

    There are two different classes of essential fatty acids: omega-6 fatty acids and omega-3 fatty acids. There is considerable evidence these fatty acids are deficient, or are not used properly, in people with schizophrenia.94,95,96,97,98,99 Some investigators suggest this altered fatty acid metabolism may be involved in the increased need for niacin seen in some schizophrenic patients.100 A case has been reported in which a man with schizophrenia had dramatic and sustained improvement while being supplemented with 2 grams daily of omega-3 fatty acids.101 In a preliminary trial, schizophrenic patients receiving omega-3 fatty acids showed improvement in symptoms, as well as a reduction in adverse effects from their anti-psychotic medications.102 Another study found that people with schizophrenia had lower blood levels of both omega-3 and omega-6 fatty acids, compared with non-schizophrenic people, even though both groups were consuming similar amounts of these fatty acids.103 In a separate preliminary study, higher intake of omega-3 fatty acids was associated with less severe disease, and supplementation with 10 grams of concentrated fish oil, a source of omega-3 fatty acids, led to significant improvement in symptoms over a six-week period.103 In a double-blind trial, supplementation with fish oil (providing 2.2 g per day of the combination of eicosapentaenoic acid and docosahexaenoic acid) for 26 weeks decreased symptom severity, compared with a placebo, in a group of patients hospitalized with a first episode of schizophrenia.105 In addition, a double-blind trial found that supplementing with 1.2 g per day of omega-3 fatty acids from fish oil prevented the development of psychosis in adolescents and young adults who were at very high risk of developing a psychotic disorder.106

    In a double-blind trial that included 87 patients with chronic schizophrenia or a related illness (schizoaffective disorder), supplementation with 3 grams per day of eicosapentaenoic acid (one of the omega-3 fatty acids found in fish oil) was ineffective.107 The patients in this negative study were older and had been ill for longer, compared with patients in earlier studies who improved with omega-3 fatty acid supplementation.

    Several clinical trials have examined the effects of supplementation with essential fatty acids in people with schizophrenia, with inconsistent results.108,109,110,111 While the results of trials using omega-3 fatty acids are promising, further double-blind trials are needed to establish whether fatty acid supplementation is an effective therapy for schizophrenia. Trials of omega-6 fatty acids (like GLA from borage oil) have yielded predominantly negative results.112

    Bipolar Disorder

    People with depression may have lower blood levels of omega-3s. Taking fish oil, in addition to prescribed medication, improved symptoms in one study.
    Bipolar Disorder
    ×

    People diagnosed with depression may have lower blood levels of omega-3 fatty acids.112,113 A double-blind trial found that bipolar patients taking 9.6 grams of omega-3 fatty acids from fish oil per day in addition to their medications had significant improvements compared with those taking placebo.114 Similar benefits were reported in a preliminary trial that used 1.5 to 2 grams per day of pure eicosapentaenoic acid, a component of fish oil.[REF] However, in another double-blind trial, 8 grams per day of fish oil taken for 4 months was of no benefit for patients with bipolar disorder.[REF] In a preliminary trial, children with bipolar disorder saw benefits from omega-3 fatty acids (1,290 to 4,300 mg per day) from fish oil given for eight weeks.115

  • Bone Support

    Osteoporosis

    Fish oil combined with evening primrose oil (EPO) may improve calcium absorption and promote bone formation.
    Osteoporosis
    ×

    A preliminary trial found that elderly women with osteoporosis who were given 4 grams of fish oil per day for four months had improved calcium absorption and evidence of new bone formation.116 Fish oil combined with evening primrose oil (EPO) may confer added benefits. In a controlled trial, women received 6 grams of a combination of EPO and fish oil, or a matching placebo, plus 600 mg of calcium per day for three years.117 The EPO/fish oil group experienced no spinal bone loss in the first 18 months and a significant 3.1% increase in spinal bone mineral density during the last 18 months.

    Osteoporosis

    Supplementing with fish oil may improve calcium absorption and promote bone formation.
    Osteoporosis
    ×

    A preliminary trial found that elderly women with osteoporosis who were given 4 grams of fish oil per day for four months had improved calcium absorption and evidence of new bone formation.118 Fish oil combined with evening primrose oil (EPO) may confer added benefits. In a controlled trial, women received 6 grams of a combination of EPO and fish oil, or a matching placebo, plus 600 mg of calcium per day for three years.119 The EPO/fish oil group experienced no spinal bone loss in the first 18 months and a significant 3.1% increase in spinal bone mineral density during the last 18 months.

  • Eye Health Support

    Macular Degeneration

    In one study, supplementing with a proprietary blend of acetyl-L-carnitine, fish oil, and coenzyme Q10 improved visual function in people with macular degeneration.
    Macular Degeneration
    ×
     

    In a double-blind study, supplementation with a proprietary blend of acetyl-L-carnitine, omega-3 fatty acids from fish oil, and coenzyme Q10 for 12 months resulted in an improvement in both visual function and in objective findings on eye examination (a decrease in the drusen-covered area on the retina).120

    Glaucoma

    Inuit people, who eat large amounts of omega-3 fatty acids, appear to have a much lower incidence of glaucoma than do Caucasians. One study found that cod liver oil (a rich source of omega-3 fatty acids) reduced intraocular pressure in animals.
    Glaucoma
    ×
     

    Surveys have shown that Inuit people, who consume large amounts of omega-3 fatty acids, have a much lower incidence of some types of glaucoma than do Caucasians. Although there have been no studies on the use of omega-3 fatty acids to treat glaucoma, one study found that cod liver oil (a rich source of omega-3 fatty acids) reduced intraocular pressure in animals.121

    Macular Degeneration

    A diet high in omega-3 fatty acids, especially from fish, has been associated with lower risks of age-related macular degeneration.
    Macular Degeneration
    ×
    An assessment of 3,654 Australians aged 49 years or older found an association between a diet high in omega-3 fatty acids from fish and a lower risk of age-related macular degeneration.122
  • Menstrual and PMS Support

    Dysmenorrhea

    A fish oil supplement containing EPA and DHA may help prevent menstrual syndromes.
    Dysmenorrhea
    ×
    Diets low in omega-3 fatty acids (EPA and DHA) have been associated with menstrual pain.123 In one double-blind trial, supplementation with fish oil, a good source of omega-3 fatty acids, led to a statistically significant 37% drop in menstrual symptoms. In that report, adolescent girls with dysmenorrhea took an unspecified amount of fish oil that provided 1,080 mg of EPA and 720 mg of DHA per day for two months to achieve this result.124 A double-blind trial found that the same amount of EPA and DHA plus 7.5 mcg per day of vitamin B12 led to a greater than 50% decrease in menstrual symptoms, but a group taking only fish oil did not obtain as much relief.125 Six grams of fish oil per day provides the approximate levels of EPA and DHA used in these trials. In another double-blind trial, 1 gram per day of fish oil significantly decreased pain intensity, compared with a placebo, in women with dysmennorhea.126

    Endometriosis

    Fish oil may reduce the severity of endometriosis, and it has been shown to improve symptoms of dysmenorrhea (painful menstruation), which may be caused by endometriosis.
    Endometriosis
    ×
     

    Animal research suggests that fish oils may reduce the severity of endometriosis,127,128 and fish oils have been shown to improve symptoms of dysmenorrhea (painful menstruation),129 which may be caused by endometriosis. Therefore, while no specific research has been done on the effects of fish oils in women with endometriosis, some health practitioners recommend several grams of fish oil per day for this condition.

  • Weight Management

    Obesity

    Fish oil and its fatty acids, EPA and DHA, may support health metabolism in people with overweight and obesity.
    Obesity
    ×
    Fish oil contains anti-inflammatory omega-3 fatty acids—primarily EPA and DHA— that may promote healthy metabolism by reducing insulin resistance and inflammatory signaling by adipose tissue.130 Fish oil and omega-3 fatty acids appear to increase the sense of fullness improve the metabolic functions of fat tissue.131 One placebo-controlled trial enrolled 65 women with overweight or obesity, as well as depression; depression symptoms were reduced and weight loss was greater in those who received a combination of 1,080 mg of EPA and 720 mg of DHA daily after 12 weeks.132 A meta-analysis of data from eleven randomized controlled trials with a combined total of 617 participants found omega-3 fatty acids from fish can improve metabolic health by reducing waist circumference and triglyceride levels in individuals with overweight and obesity, but have little effect on weight loss.133
  • Allergy and Lung Support

    Asthma

    Research shows that fish oil partially reduces reactions to allergens that can trigger asthma attacks. It has also been shown in one study to prevent exercise-induced asthma attacks.
    Asthma
    ×
     

    Double-blind research shows that fish oil partially reduces reactions to allergens that can trigger attacks in some asthmatics.134 Another double-blind study showed that fish oil supplements prevented exercise-induced asthma attacks in people with asthma.135 A few other researchers have reported small but significant improvements when asthmatics supplement with fish oil,136,137 but reviews of the research concluded that most fish oil studies showed little or no benefit.138,139 It is possible that some of these trials failed to show an improvement because they did not last long enough to demonstrate an effect. There is evidence that children who eat oily fish may have a much lower risk of getting asthma.140 Moreover, in a double-blind trial, children who received 300 mg per day of fish oil (providing 84 mg of EPA and 36 mg of DHA) experienced significant improvement of asthma symptoms.141 It should be noted that these benefits were obtained under circumstances in which exposure to food allergens and environmental allergens was strictly controlled. Though the evidence supporting the use of fish oil remains somewhat conflicting, eating more fish and supplementing with fish oil may still be worth considering, especially among children with asthma.

  • Digestive Support

    Ulcerative Colitis

    Supplementing with fish oil may help reduce inflammation and prevent relapses.
    Ulcerative Colitis
    ×
     

    Preliminary142 and double-blind trials143,144,145 have found that fish oil supplementation reduces inflammation, decreases the need for anti-inflammatory drugs, and promotes normal weight gain in people with UC. However, fish oil has not always been effective in clinical trials for UC.146 Amounts used in successful clinical trials provided 3.2 grams of EPA and 2.2 grams of DHA per day—the two important fatty acids found in fish oil.

    In a preliminary trial, people with UC significantly improved on a sugar-free, low-allergen diet with additional nutritional supplementation that included a multivitamin-mineral supplement (2–6 tablets per day); a fish oil supplement (400 mg per day); borage oil (400 mg per day); flaxseed oil (400 mg per day); and a probiotic formula containing Lactobacillus acidophilus and other species of beneficial bacteria.147 Some participants received slight variations of this regimen. Since so many different supplements were given and since the trial was not controlled, it is not possible to say which, if any, of the nutrients was responsible for the improvement observed by the researchers.

    Crohn’s Disease

    Fish oil helps relieve the inflammation of the gut that occurs in people suffering from Crohn’s disease.
    Crohn’s Disease
    ×
     

    Inflammation within the gut occurs in people suffering from Crohn’s disease. EPA and DHA, the omega-3 fatty acids found in fish oil, have anti-inflammatory activity. Though research is conflicting, there is some evidence that fish oil improves Crohn's disease symptoms. A two-year trial compared the effects of having people with Crohn’s disease eat 3.5 to 7 ounces of fish high in EPA and DHA per day or having them eat a diet low in fish.148 In that trial, the fish-eating group had a 20% relapse rate compared with 58% among those not eating fish. Salmon, herring, mackerel, albacore tuna, and sardines are all high in EPA and DHA.

    In a double-blind trial, people with Crohn’s disease who took supplements providing 2.7 g of EPA/DHA per day had a recurrence rate of 26% after one year, compared to a 59% recurrence rate among those taking placebo.149

  • Healthy Pregnancy and New Baby

    Pregnancy and Postpartum Support

    Supplementing with fish oil (providing the omega-3 fatty acids EPA and DHA) significantly reduced recurrence of premature delivery, according to one analysis.
    Pregnancy and Postpartum Support
    ×
     

    Supplementation with fish oil (providing either 2.7 g or 6.1 g per day of the omega-3 fatty acids EPA and DHA) significantly reduced recurrence of premature delivery, according to data culled from six clinical trials involving women with a high risk for such complications.150 Fish oil supplementation did not prevent premature delivery of twin pregnancies, nor did it have any preventive effect against intrauterine growth retardation or pregnancy-induced hypertension. Fish oils should be free of contaminants, such as mercury and organochlorine pesticides. Women who eat substantial amounts of certain types of seafood (e.g., swordfish, tuna) may be consuming contaminants that can increase the risk of brain and nervous system abnormalities in their offspring. Exposure to mercury and polychlorinated biphenyls (PCBs) was found to be increased in relation to maternal intake of seafood. Higher exposure to these toxic contaminants has been linked to an increased risk of deficits in the developing brains and nervous systems of the children.151

    Pregnancy and Prenatal Growth

    The DHA found in fish oil is essential for the development of the visual system in infants.
    Pregnancy and Prenatal Growth
    ×
    The DHA found in fish oil is essential for the development of the visual system in infants.152 In one double-blind study, 103 term infants were randomly assigned to receive either formula with no docosahexaenoic acid (DHA) or arachidonic acid (ARA) or formula supplemented with DHA and ARA at concentrations similar to those found in human milk, starting when they were six days old. Visual maturation was assessed by measuring sweep visual evoked potential at ages 6, 17, 26, and 52 weeks. At each age, the supplemented group measured better, which led researchers to conclude that long-term supplementation of infant formula with DHA and ARA in amounts typical in human milk may help enhance visual development during the first year of life.

    Preeclampsia

    Fish oil supplementation may lower the incidence of preeclampsia.
    Preeclampsia
    ×
     

    Fish oil supplementation has been proposed to lower the incidence of preeclampsia.153,154 However, controlled clinical trials suggest that fish oil does not reduce symptoms155 or protect against preeclampsia.156,157

  • Immune System Support

    Lupus

    Supplementing with fish oil may improve symptoms and decrease disease activity.
    Lupus
    ×
     

    The omega-3 fatty acids in fish oil—eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—decrease inflammation. Supplementation with EPA and DHA has prevented autoimmune lupus in animal research.158 In a double-blind trial, 20 grams of fish oil daily combined with a low-fat diet led to improvement in 14 of 17 people with SLE in 12 weeks.159 Other studies also found that supplementing with 10 to 15 grams of fish oil per day,160 or with the amount of EPA and DHA provided by 10 grams per day of fish oil,161 is beneficial for people with SLE. People wishing to take such a large amount of fish oil should first consult with a doctor.

    Pre- and Post-Surgery Health

    Omega-3 fatty acids, found in fish oil, have anti-inflammatory properties and may improve recovery and prevent infection after surgery.
    Pre- and Post-Surgery Health
    ×
     

    Omega-3 fatty acids have anti-inflammatory properties,162 and animal studies suggest that supplementation with omega-3 fatty acids may improve recovery and prevent infection after surgery.163,164 A controlled human trial found that intravenous nutritional formulas containing omega-3 fatty acids given post-operatively lowered the production of inflammatory chemicals compared with standard nutritional formulas.165 Other human studies of omega-3 fatty acid-supplemented nutritional formulas used in surgery patients have included other supplemental nutrients as well and are discussed below.166

    Immune Function and Post-Surgery Patients

    Most studies have reported that supplementing with omega-3s increases immune function in hospitalized post-surgery patients.
    Immune Function and Post-Surgery Patients
    ×

    Immune Function and Critically Ill Patients

    For critically ill and hospitalized patients, supplementing with fish oil appears to increase immune function.
    Immune Function and Critically Ill Patients
    ×

    Research on the effect of the omega-3 fatty acids that are abundant in some fish, fish oils, and flaxseed oil is conflicting. Liquid diets containing omega-3 fatty acids used in hospitals for critically ill people have been shown to improve immune function and reduce infections.167168 However, in one controlled study in healthy people, a low-fat diet improved or maintained immune function, but when fish was added to increase omega-3 fatty acid intake, immune function was significantly inhibited.169

    Supplementation with DHA (an omega-3 fatty acid found in fish oil) in healthy young men has been shown to decrease the activity of immune cells, such as natural killer (NK) cells, and to inhibit certain measures of inflammation in the test tube.170 The anti-inflammatory effects of DHA may be useful in the management of autoimmune disorders; however, such benefits need to be balanced with the potential for increased risk of infections. Other studies suggest that increased oxidative damage might be the reason for the negative effects on the immune system sometimes caused by fish oil, and that increased intake of antioxidants, such as vitamin E, could correct the problem.171

  • Blood Sugar and Diabetes Support

    Type 1 Diabetes

    Fish oil and its omega-3 fatty acid EPA may improve blood sugar control and help prevent complications of type 1 diabetes.
    Type 1 Diabetes
    ×

    Omega-3 fatty acids from fish are well known to reduce inflammatory immune activity and have beneficial effects in a range of autoimmune conditions. Observational research suggests higher levels during infancy and early childhood may be linked to lower risk of developing type 1 diabetes.172 One study done in Norway found that babies given cod liver oil regularly during the first year of life had a 26% lower risk of developing type 1 diabetes in childhood. However, not all studies have noted a connection between omega-3 fatty acids and type 1 diabetes risk, and some researchers have proposed the discrepancies may be explained by genetic factors affecting fatty acid metabolism.173,174

    Higher intake of EPA, an omega-3 fatty acids from fish, has been correlated with better preservation of pancreatic cells that produce insulin and long-term blood glucose control in youth with type 1 diabetes.175,176 A small pilot trial found that supplementation with 630 mg of EPA and 330 mg of DHA (another omega-3 fatty acid from fish oil) per day improved blood glucose control in subjects with type 1 diabetes.177 Furthermore, better omega-3 fatty acid status may be helpful in slowing the progression of diabetes-associated complications such as kidney dysfunction and nerve pain.178,179

    Although fish oil fatty acids generally have positive effects on triglyceride levels, some studies have found supplemental DHA can increase LDL- and total cholesterol, which may increase cardiac risk. For this reason, some doctors are wary of fish oil supplements for patients with type 1 diabetes and may recommend EPA-only supplements instead.180

    Type 2 Diabetes

    Supplementing with fish oil can reduce inflammation and may lower triglyceride and cholesterol levels in people with type 2 diabetes.
    Type 2 Diabetes
    ×
    Fish oil and its polyunsaturated omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been widely studied for their potential metabolic benefits. Clinical trials have reported conflicting evidence, with some studies finding positive effects, some no effects, and some negative effects of fish oil consumption on markers of metabolic health in people with type 2 diabetes.181 Attempting to explain these inconsistencies, one analysis suggested omega-3 fatty acids may be more beneficial in women than men.182 Nevertheless, a large meta-analysis that pooled findings from 45 randomized controlled trials with a combined total of 2,674 participants with type 2 diabetes found an overall positive effect of omega-3 fatty acids from fish on levels of markers of systemic inflammation, triglycerides, total cholesterol, LDL-cholesterol, and VLDL-cholesterol levels, as well as a small but statistically significant positive effect on HbA1c.183 Another meta-analysis of 17 studies with a total of 672 participants found omega-3 fatty acids from fish could improve insulin sensitivity in people with metabolic disorders, including type 2 diabetes.184
  • Pain Management

    Migraine Headache

    Fish oil containing EPA and DHA has been reported to reduce migraine headache symptoms. Fish oil may help because of its effects in modifying hormone-like substances called prostaglandins.
    Migraine Headache
    ×
     

    Fish oil containing EPA and DHA has been reported to reduce the symptoms of migraine headache in a double-blind trial using 1 gram of fish oil per 10 pounds of body weight.185,186 Fish oil may help because of its effects in modifying prostaglandins (hormone-like substances made by the body).

  • Energy Support

    Chronic Fatigue Syndrome

    In one study, patients with chronic fatigue syndrome reported an improvement in their symptoms after taking a supplement containing the essential fatty acids EPA and DHA.
    Chronic Fatigue Syndrome
    ×
     

    In a preliminary study, four patients with chronic fatigue syndrome reported an improvement in their symptoms after taking an essential fatty acid supplement daily for at least 12 weeks.187 The amount used was 10 to 18 capsules per day, and each capsule contained 93 mg of eicosapentaenoic acid (EPA), 29 mg of docosahexaenoic acid (DHA), and 10 mg of gamma-linolenic acid. Because there was no placebo group in this study and, because fatigue often improves after treatment with a placebo, additional research is needed to confirm this report.

What Are Star Ratings?
×
Reliable and relatively consistent scientific data showing a substantial health benefit.
Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support.

Our proprietary “Star-Rating” system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people.

For over a decade, our team has combed through thousands of research articles published in reputable journals. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. We hope this provides you with a helpful resource to make informed decisions towards your health and well-being.

Temp Title
×
Temp Text

References

1. Prichard BN, Smith CCT, Ling KLE, Betteridge DJ. Fish oils and cardiovascular disease. BMJ 1995;310:819-20 [editorial/review].

2. Von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest 1985;76:1626-31.

3. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988;318:549-57 [review].

4. Adler AJ, Holub BJ. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. Am J Clin Nutr 1997;65:445-50.

5. Haglund O, Luostarinen R, Wallin R, et al. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr 1991;121:165-9.

6. Oostenbrug GS, Mensink RP, Hornstra G. A moderate in vivo vitamin E supplement counteracts the fish-oil-induced increase in in vitro oxidation of human low-density lipoproteins. Am J Clin Nutr 1993;57:827S.

7. Bercea CI, Cottrell GS, Tamagnini F, et al. Omega-3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid. Br J Pharmacol 2021;178:860–77.

8. Matsumoto C, Yoruk A, Wang L, et al. Fish and omega-3 fatty acid consumption and risk of hypertension. J Hypertens 2019 06;37(6):1223–9.

9. Yang B, Shi MQ, Li ZH, et al. Fish, Long-Chain n-3 PUFA and Incidence of Elevated Blood Pressure: A Meta-Analysis of Prospective Cohort Studies. Nutrients 2016 Jan;8(1):58.

10. Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens 2014 Jul;27(7):885–96.

11. Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30.

12. Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011;57:870-9.

13. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999;10:2177-84.

14. Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993;4:53-60.

15. Phillipson BE, Rothrock DW, Connor WE, et al. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985;312:1210-6.

16. Haglund O, Wallin R, Luostarinen R, Saldeen T. Effects of a new fluid fish oil concentrate, ESKIMO-3, on triglycerides, cholesterol, fibrinogen and blood pressure. J Intern Med 1990;227:347-53.

17. Haglund O, Luostarinen R, Wallin W, Saldeen T. Effects of fish oil on triglycerides, lipoprotein(a), atherogenic index and fibrinogen. Influence of the degree of purification of the oil. Nutr Res 1992;12:455-68.

18. Haglund O, Luostarinen R, Wallin R, et al. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr 1991;121:165-9.

19. Leng GC, Lee AJ, Fowkes FG, et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin Nutr 1998;17:265-71.

20. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248-57.

21. Sacks FM, Stone PH, Gibson CM, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995;25:1492-8.

22. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;130:554-62.

23. Saynor R, Verel D, Gillott T. The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis 1984;50:3-10.

24. Mehta JL, Lopez LM, Lawson D, et al. Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease. Effects on indices of platelet and neutrophil function and exercise performance. Am J Med 1988;84:45-52.

25. Wander RC, Du SH, Ketchum SO, Rowe KE. Alpha-tocopherol influences in vivo indices of lipid peroxidation in postmenopausal women given fish oil. J Nutr 1996;126:643-52.

26. Oostenbrug GS, Mensink RP, Hornstra G. A moderate in vivo vitamin E supplement counteracts the fish-oil-induced increase in in vitro oxidation of human low-density lipoproteins. Am J Clin Nutr 1993;57:827S.

27. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;130:554-62.

28. Singh RB, Niaz MA, Sharma JP, et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4. Cardiovasc Drugs 1997;11:485-91.

29. [No authors listed]. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.

30. Landmark K, Abdelnoor M, Urdal P, et al. Use of fish oils appears to reduce infarct size as estimated from peak creatine kinase and lactate dehydrogenase activities. Cardiology 1998;89:94-102.

31. Wander RC, Du SH, Ketchum SO, Rowe KE. Alpha-tocopherol influences in vivo indices of lipid peroxidation in postmenopausal women given fish oil. J Nutr 1996;126:643-52.

32. Carrero JJ, Lopez-Huertas E, Salmeron LM, et al. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr2005;135:1393-9.

33. Digiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med 1989;86:158-64.

34. Sellmayer A, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol 1995;76:974-7.

35. Hardarson T, Kristinsson A, Skuladottir G, et al. Cod liver oil does not reduce ventricular extrasystoles after myocardial infarction. J Intern Med 1989;236:33-7.

36. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators. A randomized controlled trial. JAMA 2005;293:2884-91

37. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA2006;295:2613-9.

38. Shahar E, Folsom AR, Melnick SL, et al. Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1994;331:228-33.

39. Broekhuizen R, Wouters EFM, Creutzberg EC, et al. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax 2005;60:376-82.

40. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998;48:149-55.

41. Maes M, Smith R, Christophe A, et al. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996;38:35-46.

42. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315-9.

43. Maes M, Christophe A, Delanghe J, et al. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275-91.

44. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996;31:S157-S161.

45. Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006;163:1098-100.

46. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-71.

47. Grenyer BFS, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1393-6.

48. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008;99:421-31.

49. Puri BK, Counsell SJ, Richardson AJ, Horrobin DF. Eicosapentaenoic acid in treatment-resistant depression. Arch Gen Psychiatry 2002;59:91-92 [Letter].

50. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-9.

51. Buydens-Branchey L, Branchey M. n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 2006;26:661-5.

52. Deutch B. Menstrual pain in Danish women correlated with low n-3 polyunsaturated fatty acid intake. Eur J Clin Nutr 1995;49:508-16.

53. Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174:1335-8.

54. Deutch B, Jørgensen EB, Hansen JC. Menstrual discomfort in Danish women reduced by dietary supplements of omega-3 PUFA and B12 (fish oil or seal oil capsules). Nutr Res 2000;20:621-31.

55. Zafari, M., Tofighi, M, Aghamohammady, A., Behmanesh, F., and Rakhshaee, Z. Comparison of the effect of fish oil and ibuprofen on treatment of severe pain in primary dysmenorrhea. Caspian J Intern Med. 2011 Summer;2(3):279-82.

56. Olsen SF, Secher NJ, Tabor A, et al. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. Brit J Obstet Gynecol 2000;107:382-95.

57. Steuerwald U, Weihe P, Jorgensen PJ, et al. Maternal seafood diet, methylmercury exposure, and neonatal neurologic function. J Pediatr 2000;136:599-605.

58. Birch EE, Castaneda YS, Wheaton DH, Birch DG, Uauy RD, Hoffman DR. Visual maturation of term infants fed long-chain polyunsaturated fatty acid-supplemented or control formula for 12 mo. Am J Clin Nutr 2005;81:871-9.

59. Yano Y. Effect of dietary supplementation with eicosapentaenoic acid on surgically induced endometriosis in the rabbit. Nippon Sanka Fujinka Gakkai Zasshi 1992 Mar;44(3):282-8 [in Japanese].

60. Covens AL, Christopher P, Casper RF. The effect of dietary supplementation with fish oil fatty acids on surgically induced endometriosis in the rabbit. Fertil Steril 1988;49:698-703.

61. Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174:1335-8.

62. Feher J, Kovacs B, Kovacs I, et al. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica2005;219:154-66.

63. Chua B, Flood V, Rochtchina E, Wang JJ, Smith W, Mitchell P. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol 2006;124:981-6.

64. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006;63:1402-8.

65. Kremer JM, Jubiz W, Michalek A, et al. Fish­oil fatty acid supplementation in active rheumatoid arthritis. Ann Int Med 1987;106(4):497-503.

66. Kremer JM, Lawrence DA, Jubiz W, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 1990;33:810-20.

67. Geusens P, Wouters C, Nijs J, et al. Long­term effect of omega­3 fatty acid supplementation in active rheumatoid arthritis. Arthrit Rheum 1994;37:824-9.

68. Van der Tempel H, Tulleken JE, Limburg PC, et al. Effects of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis 1990;49:76-80.

69. Cleland LG, French JK, Betts WH, et al. Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol 1988;15(10):1471-5.

70. Kremer JM, Lawrence DA, Petrillow GF, et al. Effects of high­dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Arthritis Rheum 1995;38:1107-14.

71. Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology 2008;47:665-9.

72. Proudman SM, James MJ, Spargo LD, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 2015;74:89–95.

73. Rajaei E, Mowla K, Ghorbani A, et al. The effect of omega-3 fatty acids in patients with active rheumatoid arthritis receiving DMARDs therapy: double-blind randomized controlled trial. Glob J Health Sci 2015;8:18–25.

74. Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985;312(19):1217-24.

75. Nordstrom DC, Honkanen VE, Nasu Y, et al. Alpha-linolenic acid in the treatment of rheumatoid arthritis. A double-blind, placebo-controlled and randomized study: flaxseed vs. safflower seed. Rheumatol Int 1995;14:231-4.

76. Altman R, Gray R. Inflammation in osteoarthritis. Clin Rheum Dis 1985;11:353.

77. Stammers T, Sibbald B, Freeling P. Fish oil in osteoarthritis. Lancet 1989;ii:503 [letter].

78. Stammers T, Sibbald B, Freeling P. Efficacy of cod liver oil as an adjunct to non-steroidal anti-inflammatory drug treatment in the management of osteoarthritis in general practice. Ann Rheum Dis 1992;51:128-9.

79. Bittiner SB, Tucker WFG, Cartwright I, Bleehen SS. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet 1988;i:378-80.

80. Kojima T, Terano T, Tanabe E, et al. Long-term administration of highly purified eicosapentaenoic acid provides improvement of psoriasis. Dermatologica 1991;182:225-30.

81. Kojima T, Ternao T, Tanabe E, et al. Effect of highly purified eicosapentaenoic acid on psoriasis. J Am Acad Dermatol 1989;21:150-1.

82. Soyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med 1993;328:1812-6.

83. Dewsbury CE, Graham P, Darley CR. Topical eicosapentaenoic acid (EPA) in the treatment of psoriasis. Br J Dermatol 1989;120:581-4.

84. Mayser P, Mrowietz U, Arenberger P, et al. W-3 Fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol 1998;38:539-47.

85. Ashley JM, Lowe NJ, Borok ME, Alfin-Slater RB. Fish oil supplementation results in decreased hypertriglyceridemia in patients with psoriasis undergoing etretinate or acitretin therapy. J Am Acad Dermatol 1988;19:76-82.

86. Bjørneboe A, Søyland E, Bjørneboe GE, et al. Effect of dietary supplementation with eicosapentaenoic acid in the treatment of atopic dermatitis. Br J Dermatol 1987;117:463-9.

87. Bjørnboe A, Søyland E, Bjørnboe GE, et al. Effect of n-3 fatty acid supplement to patients with atopic dermatitis. J Intern Med Suppl 1989;225:233-6.

88. Søyland E, Rajka G, Bjørneboe A, et al. The effect of eicosapentaenoic acid in the treatment of atopic dermatitis. A clinical Study. Acta Derm Venereol (Stockh) 1989;144(Suppl):139.

89. Berth-Jones J, Graham-Brown RAC. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. Lancet 1993;341:1557-60.

90. Søyland E, Funk J, Rajka G, et al. Dietary supplementation with very long-chain n-3 fatty acids in patients with atopic dermatitis. A double-blind multicentre study. Br J Dermatol 1994;130:757-64.

91. Rhodes LE, Durham BH, Fraser WD, Friedmann PS. Dietary fish oil reduces basal and ultraviolet B-generated PGE2 levels in skin and increases the threshold to provocation of polymorphic light eruption. J Invest Dermatol 1995;105:532-5.

92. McBeath EC, Zucker TF. The role of vitamin D in the control of dental caries in children. J Nutr 1938;15:547-64.

93. Buydens-Branchey L, Branchey M. n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 2006;26:661-5.

94. Horrobin DF. The relationship between schizophrenia and essential fatty acid and eicosanoid metabolism. Prostaglandins Leukot Essent Fatty Acids 1992;46:71-7 [review].

95. Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 1996;55:3-7 [review].

96. Warner R, Laugharne J, Peet M, et al. Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study. Biol Psychiatry 1999;45:1138-42.

97. Mahadik SP, Mukherjee S, Horrobin DF, et al. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res 1996;63:133-42.

98. Vaddadi KS, Gilleard CJ, Soosai E, et al. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr Res 1996;20:287-94.

99. Peet M, Laugharne J, Rangarajan N, et al. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 1995;29:227-32.

100. Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 1981;16:837-50.

101. Puri BK, Richardson AJ, Horrobin DF, et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int J Clin Pract 2000;54:57-63.

102. Peet M, Laugharne JD, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 1996;55:71-5.

103. Laugharne JD, Mellor JE, Peet M. Fatty acids and schizophrenia. Lipids 1996;31 Suppl:S163-5.

104. Pawełczyk T, Grancow-Grabka M, Kotlicka-Antczak M, et al. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 2016;73:34–44.

105. Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-54.

106. Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001;158:2071-4.

107. Vaddadi KS, Courtney P, Gilleard CJ, et al. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989;27:313-23.

108. Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Hum Psychopharmacol 1996;11:39-46.

109. Shah S, Ramchand CN, Peet M. Eicosapentaenoic acid (EPA) as an adjunct to neuroleptic therapy in the treatment of schizophrenia. Presented at the 9th Schizophrenia Winter Workshop, Davos, Switzerland, February 7-13, 1998.

110. Mellor JE, Peet M. Double-blind, placebo-controlled, trial of omega-3 fatty acids as an adjunct to the treatment of schizophrenia. Presented at the 9th Schizophrenia Winter Workshop, Davos, Switzerland, February 7-13, 1998.

111. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000;47:8-21 [review].

112. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996;31:S157-S161.

113. Maes M, Christophe A, Delanghe J, et al. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275-91.

114. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder. A preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatr 1999;56:407-12.

115. Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007;17:440-7.

116. Van Papendorp DH, Coetzer H, Kruger MC. Biochemical profile of osteoporotic patients on essential fatty acid supplementation. Nutr Res 1995;15:325–34.

117. Kruger MC, Coetzer H, de Winter R, et al. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging 1998;10:385-94.

118. Van Papendorp DH, Coetzer H, Kruger MC. Biochemical profile of osteoporotic patients on essential fatty acid supplementation. Nutr Res 1995;15:325–34.

119. Kruger MC, Coetzer H, de Winter R, et al. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging 1998;10:385-94.

120. Feher J, Kovacs B, Kovacs I, et al. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica2005;219:154-66.

121. McGuire R. Fish oil cuts lower ocular pressure. Med Tribune 1991;Sept 19:25.

122. Chua B, Flood V, Rochtchina E, Wang JJ, Smith W, Mitchell P. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol 2006;124:981-6.

123. Deutch B. Menstrual pain in Danish women correlated with low n-3 polyunsaturated fatty acid intake. Eur J Clin Nutr 1995;49:508-16.

124. Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174:1335-8.

125. Deutch B, Jørgensen EB, Hansen JC. Menstrual discomfort in Danish women reduced by dietary supplements of omega-3 PUFA and B12 (fish oil or seal oil capsules). Nutr Res 2000;20:621-31.

126. Zafari, M., Tofighi, M, Aghamohammady, A., Behmanesh, F., and Rakhshaee, Z. Comparison of the effect of fish oil and ibuprofen on treatment of severe pain in primary dysmenorrhea. Caspian J Intern Med. 2011 Summer;2(3):279-82.

127. Yano Y. Effect of dietary supplementation with eicosapentaenoic acid on surgically induced endometriosis in the rabbit. Nippon Sanka Fujinka Gakkai Zasshi 1992 Mar;44(3):282-8 [in Japanese].

128. Covens AL, Christopher P, Casper RF. The effect of dietary supplementation with fish oil fatty acids on surgically induced endometriosis in the rabbit. Fertil Steril 1988;49:698-703.

129. Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174:1335-8.

130. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv Nutr 2011 Jul;2(4):304–16.

131. Albracht-Schulte K, Kalupahana NS, Ramalingam L, et al. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J Nutr Biochem 2018 08;58:1–16.

132. Keshavarz SA, Mostafavi SA, Akhondzadeh S, et al. Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. Clin Nutr ESPEN 2018 06;25:37–43.

133. Zhang YY, Liu W, Zhao TY, et al. Efficacy of Omega-3 Polyunsaturated Fatty Acids Supplementation in Managing Overweight and Obesity: A Meta-Analysis of Randomized Clinical Trials. J Nutr Health Aging 2017;21(2):187–92.

134. Arm JP, Horton CE, Eiser NM, et al. The effects of dietary supplementation with fish oil on asthmatic responses to antigen. J Allergy Clin Immunol 1988;81:183 [abstract #57].

135. Mickleborough TD, Lindley MR, Ionescu AA, Fly AD. Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest2006;129:39-49.

136. Broughton KS, Johnson CS, Pace BK, et al. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. Am J Clin Nutr 1997;65:1011-7.

137. Dry J, Vincent D. Effect of a fish oil diet on asthma: results of a 1-year double-blind study. Int Arch Allergy Appl Immunol 1991;95:156-7.

138. Thien FC, Woods RK, Waters EH. Oily fish and asthma—a fishy story? Med J Aust 1996;164:135-6 [editorial].

139. Fogarty A, Britton J. The role of diet in the aetiology of asthma. Clin Exp Allergy 2000;30:615-27.

140. Hodge L, Salome CM, Peat JK, et al. Consumption of oily fish and childhood asthma risk. Med J Austral 1996;164:137-40.

141. Nagakura T, Matsuda S, Shichijyo K, et al. Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. Eur Respir J 2000;16:861-5.

142. Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n--3-omega-fatty acid: an open trial. J Clin Gastroenterol 1990;12:157-61.

143. Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992;116:609-14.

144. Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33:922-8.

145. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 1992;87:432-7.

146. Dichi I, Frenhane P, Dichi JB, et al. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. Nutrition 2000;16:87-90.

147. Edman JS, Williams WH, Atkins RC. Nutritional therapies for ulcerative colitis: literature review, chart review study, and future research. Altern Ther Health Med 2000;6:55-63.

148. Mate J, Castanos R, Garcia-Samaniego J, Pajares JM. Does dietary fish oil maintain the remission of Crohn's disease: a case control study. Gastroenterology 1991;100:A228 [abstract].

149. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.

150. Olsen SF, Secher NJ, Tabor A, et al. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. Brit J Obstet Gynecol 2000;107:382-95.

151. Steuerwald U, Weihe P, Jorgensen PJ, et al. Maternal seafood diet, methylmercury exposure, and neonatal neurologic function. J Pediatr 2000;136:599-605.

152. Birch EE, Castaneda YS, Wheaton DH, Birch DG, Uauy RD, Hoffman DR. Visual maturation of term infants fed long-chain polyunsaturated fatty acid-supplemented or control formula for 12 mo. Am J Clin Nutr 2005;81:871-9.

153. Sibai BM. Prevention of preeclampsia: A big disappointment. Am J Obstet Gynecol 1998;179:1275-8 [review].

154. Williams MA, Zingheim RW, King IB, Zebelman AM. Omega-3 fatty acids in maternal erythrocytes and risk for preeclampsia. Epidemiology 1995;6:232-7.

155. Laivuori H, Hovatta O, Viinikka L, Ylikorkala O. Dietary supplementation with primrose oil or fish oil does not change urinary excretion of prostacyclin and thromboxane metabolites in pre-eclamptic women. Prostaglandins Leukot Essent Fatty Acids 1993;49:691-4.

156. Onwude JL, Lilford RJ, Hjartardottier H, et. al. A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. Br J Obstet Gynaecol 1995;109:95-100.

157. Salvig JD, Olsen SF, Secher NJ. Effects of fish oil supplementation in late pregnancy on blood pressure: a randomised controlled trial. Br J Obstet Gynaecol 1996;103:529-33.

158. Kelley VE, Ferretti A, Izui S, Strom TB. A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-1pr mice. J Immunol 1985;134:2914-9.

159. Walton AJE, Snaith ML, Locniskar M, et al. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 1991;50:463-6.

160. Westberg G, Tarkowski A. Effect of MaxEPA in patients with SLE. Scand J Rheumatology 1990;19:137-43.

161. Wright SA, O'Prey FM, McHenry MT, et al. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008;67:841-8.

162. Gerster H. The use of n-3 PUFAs (fish oil) in enteral nutrition. Int J Vitam Nutr Res 1995;65:3-20 [review].

163. Kollman KA, Lien EL, Vanderhoof JA. Dietary lipids influence intestinal adaptation after massive bowel resection. J Pediatr Gastroenterol Nutr 1999;28:41-5.

164. Johnson JA 3d, Griswold JA, Muakkassa FF. Essential fatty acids influence survival in sepsis. J Trauma 1993;35:128-31.

165. Wachtler P, Konig W, Senkal M, et al. Influence of a total parenteral nutrition enriched with omega-3 fatty acids on leukotriene synthesis of peripheral leukocytes and systemic cytokine levels in patients with major surgery. J Trauma 1997;42:191-8.

166. Gianotti L, Braga M, Fortis C, et al. A prospective, randomized clinical trial on perioperative feeding with an arginine-, omega-3 fatty acid-, and RNA-enriched enteral diet: effect on host response and nutritional status. JPEN J Parenter Enteral Nutr 1999;23:314-20.

167. Tashiro T, Yamamori H, Takagi K, et al. n-3 versus n-6 polyunsaturated fatty acids in critical illness. Nutrition 1998;14:551-3.

168. Gerster H. The use of n-3 PUFAs (fish oil) in enteral nutrition. Int J Vitam Nutr Res 1995;65:3-20 [review].

169. Meydani SN, Lichtenstein AH, Cornwall S, et al. Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest 1993;92:105-13.

170. Kelley DS, Taylor PC, Nelson GJ, et al. Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids 1999;34:317-24.

171. Wu D, Meydani SN. n-3 polyunsaturated fatty acids and immune function. Proc Nutr Soc 1998;57:503-9 [review].

172. Niinisto S, Takkinen H, Erlund I, et al. Fatty acid status in infancy is associated with the risk of type 1 diabetes-associated autoimmunity. Diabetologia 2017;60:1223–33.

173. Norris J, Kroehl M, Fingerlin T, et al. Erythrocyte membrane docosapentaenoic acid levels are associated with islet autoimmunity: The Diabetes Autoimmunity Study in the Young. Diabetologia 2014;57:295–304.

174. Miller M, Yin X, Seifert J, et al. Erythrocyte membrane omega-3 fatty acid levels and omega-3 fatty acid intake are not associated with conversion to type 1 diabetes in children with islet autoimmunity: the Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2011;12:669–75.

175. Lamichhane A, Crandell J, Jaacks L, et al. Longitudinal associations of nutritional factors with glycated hemoglobin in youth with type 1 diabetes: the SEARCH Nutrition Ancillary Study. Am J Clin Nutr 2015;101:1278–85.

176. Mayer-Davis E, Dabelea D, Crandell J, et al. Nutritional factors and preservation of C-peptide in youth with recently diagnosed type 1 diabetes: SEARCH Nutrition Ancillary Study. Diabetes Care 2013;36:1842–50.

177. Stiefel P, Ruiz-Gutierrez V, Gajon E, et al. Sodium transport kinetics, cell membrane lipid composition, neural conduction and metabolic control in type 1 diabetic patients. Changes after a low-dose n-3 fatty acid dietary intervention. Ann Nutr Metab 1999;43:113–20.

178. Lee C, Sharp S, Wexler D, Adler A. Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial. Diabetes Care 2010;33:1454–6.

179. Lewis E, Perkins B, Lovblom L, et al. Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. Neurology 2017;88:2294–301.

180. Gutstein A, Copple T. Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same. J Am Assoc Nurse Pract 2017;29:791–801.

181. Telle-Hansen V, Gaundal L, Myhrstad M. Polyunsaturated Fatty Acids and Glycemic Control in Type 2 Diabetes. Nutrients 2019;11.

182. Abbott K, Burrows T, Thota R, et al. Do omega-3 PUFAs affect insulin resistance in a sex-specific manner? A systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2016;104:1470–84.

183. O'Mahoney L, Matu J, Price O, et al. Omega-3 polyunsaturated fatty acids favorably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol 2018;17:98.

184. Gao H, Geng T, Huang T, Zhao Q. Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis. Lipids Health Dis 2017;16:131.

185. McCarren T, Hitzemann R, Allen C, et al. Amelioration of severe migraine by fish oil (omega-3) fatty acids. Am J Clin Nutr 1985;41:874 [abstract].

186. Glueck CJ, McCarren T, Hitzemann R, et al. Amelioration of severe migraine with omega-3 fatty acids: a double-blind placebo controlled clinical trial. Am J Clin Nutr 1986;43:710 [abstract].

187. Puri BK. The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome. Prostaglandins Leukot Essent Fatty Acids 2004;70:399-401.

188. Gaby, AR. Nutritional Medicine. Concord, NH: Fritz Perlberg Publishing, 2011.

189. Belluzzi A, Brignola C, Campieri M, et al. Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. Dig Dis Sci 1994;39:2589-94.

190. Burns CP, Halabi S, Clamon GH, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999;5:3942-7.

191. Maes M, Smith R, Christophe A, et al. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996;38:35-46.

192. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998;48:149-55.

193. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315-9.

194. Maes M, Christophe A, Delanghe J, et al. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275-91.

195. Navarro E, Esteve M, Olivé A, et al. Abnormal fatty acid pattern in rheumatoid arthritis. A rationale for treatment with marine and botanical lipids. J Rheumatol 2000;27:298-303.

196. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988;318:549-57 [review].

197. Malasanos TH, Stacpoole PW. Biological effects of omega-3 fatty acids in diabetes mellitus. Diabetes Care 1991;14:1160-79.

198. Schectman G, Kaul S, Kassebah AH. Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes 1988;37:1567-73.

199. Toft I, Bonaa KH, Ingebretsen OC, et al. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. Ann Intern Med 1995;123:911-8.

200. Dunstan DW, Burke V, Mori TA, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. Diabetes Care 1997;20:913-21.

201. Harris WS, Zucker ML, Dujovne CA. Omega-3 fatty acids in type IV hyperlipidemia: fish oils vs. methyl esters. Am J Clin Nutr 1987;45:858 [abstract].

202. Kmet A, Unger J, Jahangir K, Kolber MR. Fish-oil capsule ingestion: a case of recurrent anaphylaxis. Can Fam Physician 2012;58:e379-81.

Copyright © 2025 TraceGains, Inc. All rights reserved.

Learn more about TraceGains, the company.

The information presented by TraceGains is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2025.